TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
AssigneesJiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
InventorsChenmin TIAN, Hao LI, Xun LIU
Life of this patent
Estimating the term…
Abstract
Disclosed in the present disclosure are a TGF-β receptor fusion protein pharmaceutical composition and a use thereof. Specifically, the pharmaceutical composition comprises a TGF-β receptor fusion protein in a sodium citrate buffer, and the TGF-β receptor fusion protein comprises a PD-L1 antibody targeting portion and a TGF-βRII extracellular region. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant.
Claims24
A pharmaceutical composition comprising:
- a TGF-β receptor fusion protein, and
- a buffer;
- wherein, the buffer is selected from the group consisting of a histidine salt buffer, a succinate buffer, and a citrate buffer;
- wherein the TGF-β receptor fusion protein is shown as general formula (I):
- Ab-L-TGF-βRII ECD (I)
- wherein:
- Ab is a PD-L1 antibody or antigen-binding fragment thereof;
- L is a linker sequence;
- and
- the sequence of TGF-βRII ECD is shown as SEQ ID NO:
- 14, 15, 16 or 17.
The pharmaceutical composition according to claim 41, wherein the linker sequence is shown as (G4S)xG, wherein x is 3, 4, 5 or 6.
(canceled)
Dependencies are inferred from the claim text.